Longitudinal thrombopoietin plasma concentrations in fetuses with alloimmune thrombocytopenia treated with intrauterine PLT transfusions.
BACKGROUND
The purpose of this study was to describe longitudinal thrombopoietin (TPO) plasma concentrations in fetuses with fetomaternal alloimmune thrombocytopenia (FMAIT).


METHODS
Group 1 was the control group, 8 fetuses with normal hematopoiesis. Group 2 consisted of 4 nonthrombocytopenic fetuses with fetomaternal human PLT antigen incompatibility. Group 3 consisted of 14 fetuses with prenatal-diagnosed severe FMAIT owing to human PLT antigen-1a incompatibility. Fetal PLT counts, MoAb-specific immobilization of PLT antigen score, and TPO plasma concentrations were measured in a total number of 94 serial samples taken by cordocentesis before intrauterine PLT transfusion.


RESULTS
Normal fetal TPO plasma concentrations ranged between 15 and 119 pg per mL (Group 1 median, 67 pg/mL). In fetuses with risk of FMAIT but normal PLT counts, TPO concentrations were normal (Group 2 median, 72 pg/mL; range, <15-158 pg/mL). In FMAIT with thrombocytopenia, the median TPO concentration was significantly higher than in Groups 1 and 2 (Group 3 median, 172 pg/mL; range, 15-623 pg/mL; p < 0.001). In the longitudinal analysis, TPO concentrations remained constant (n = 8), peaked only transiently (n = 3), or increased at the end of gestation (n = 3). Elevated TPO concentrations (592 and 623 pg/mL) were detected in one patient, who already had intracranial hemorrhage in utero.


CONCLUSIONS
TPO concentrations are normal or slightly elevated in FMAIT. Further clinical information can be provided by the longitudinal analysis of TPO concentrations in severe FMAIT.
Cremer
Malte
M
Department of Neonatology, University of Bonn, Bonn, Germany. malte.cremer@charite.de
Dame
Christof
C
Schaeffer
Hans J
HJ
Giers
Guenther
G
Bartmann
Peter
P
Bald
Rainer
R
D016824:Antigens, Human Platelet / Q000276:immunology; D001805:Blood Transfusion, Intrauterine; D005260:Female; D005315:Fetal Diseases / Q000097:blood* / Q000628:therapy*; D006801:Humans; D008137:Longitudinal Studies; D017713:Platelet Transfusion; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000628:therapy; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood* / Q000628:therapy*; D013926:Thrombopoietin / Q000097:blood*
D016824:Antigens, Human Platelet; D013926:Thrombopoietin